Unlike other major conferences, the San Antonio Breast Cancer Symposium (SABCS) has a unique ability to incorporate practice-changing data released just days before the event. This rapid presentation gets crucial information to clinicians, regulatory bodies like the FDA, and patients nearly six months faster than waiting for the next major meeting, speeding up drug review and approval processes.
When a patient has both ESR1 and PIK3CA pathway mutations, the choice between an oral SERD and a PI3K/AKT inhibitor is not straightforward. For patients with a low tumor burden and endocrine-sensitive disease, a better-tolerated single-agent oral SERD is preferred. For those with a higher disease burden, the more aggressive combination therapy is warranted.
The hyperglycemia caused by PI3K inhibitors is a direct on-target effect. These drugs inhibit the PI3K pathway, which is the same pathway insulin uses to signal glucose to enter cells. This mechanistic understanding explains why giving insulin is ineffective for managing this side effect. Instead, oral agents like metformin or GLP-1s are required.
As CDK4/6 inhibitors move into the adjuvant setting, a new, unstudied patient population is emerging: those who relapse after receiving this combination early. Current metastatic trial data does not apply to these patients, creating a clinical evidence gap and forcing oncologists to extrapolate treatment decisions until new, dedicated studies are completed.
Clinical experience reveals significant geographic and ethnic variations in drug tolerability that are not always captured in global trials. For example, Asian patients often experience severe stomatitis with everolimus, while Hispanic patients in San Antonio with high rates of prediabetes face greater challenges with hyperglycemia from PI3K/AKT inhibitors, requiring different management strategies.
To manage the common rash associated with the AKT inhibitor capivasertib, clinicians should prescribe non-sedating antihistamines twice daily. Crucially, patients should begin taking the antihistamine the day *before* starting capivasertib and continue for at least four weeks. This preemptive approach significantly reduces the incidence and severity of the rash.
Instead of starting all three drugs in a triplet combination simultaneously, a more effective clinical approach is to introduce them sequentially. By starting one drug, then adding the second, and finally the third over a period of weeks or months, clinicians can more easily identify the source of any toxicities, leading to better management and improved patient compliance.
A key heuristic for deciding between second-line endocrine therapy versus chemotherapy/ADC is the duration of benefit from the first-line CDK4/6 inhibitor. Patients who progress after a long duration (e.g., >18 months) are likely still endocrine-sensitive and should receive further endocrine-based therapy. Rapid progression (e.g., <6 months) suggests endocrine resistance, warranting a potential switch in modality.